Phase 1 N=62 Muscle Perfusion and Protein Metabolism in Elderly
Aging
Primary: Mixed Muscle Fractional Synthesis Rate (FSR) — 0.061; 0.070; 0.066; 0.070 Fractional Synthesis Rate (pecent/hour)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=41 A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in Elderly
Skeletal Muscle Mitochondrial Dysfunction in the Elderly
Primary: Change From Baseline in ATPmax (Maximal ATP Synthetic Rate) — 0.17; 0.12; 0.09; 0.06 mM/sec
N/A N=35 Mitochondrial Function in Circulating Cells and Muscle Tissue
Healthy · Obesity · Insulin Sensitivity
Primary: Mitochondrial Function in Circulating Cells and Muscle Tissue in Young Women — 26.48; 30.46; 120.04; 140.43 pmol O2/min per 400K cells
N/A N=68 Blood Flow, Muscle Regeneration and Sarcopenia
Sarcopenia
Primary: Muscle Satellite Cells — 3.2; 3.2; 4.0; 3.8 Number of Pax7+ cells/muscle fiber
N/A N=14 Vascular Dysfunction During Physical Inactivity
Aging · Vascular Endothelium · Skeletal Muscle
Primary: Brachial Artery Vascular Function — 5.1; 3.1; 4.4 percent vasodilation
Phase 2 N=64 Nitrites, Skeletal Muscle Mitochondrial Bioenergetics, and Physical Activity in Old Age
Aging · Sedentary Lifestyle · Frailty
Primary: Skeletal Muscle Mitochondrial Respiration State 3; Baseline to 12-week Change. — 2.2; -0.8 pmol O2/s/mg DW — p=0.9017
N/A N=14 Muscle Capillarization and Sarcopenia
Sarcopenia
Primary: Skeletal Muscle Capillarization — 0.4; 0.2 capillaries per muscle fiber — p=0.27
Phase 3 N=28 Carnitine Supplementation and Skeletal Muscle Function
Sarcopenia
Primary: Blood Inflammatory Marker — 2.6; 1.8; 2.9; 1.7 mg·L^-1
N/A N=20 Preventing the Loss of Muscle and Function in Hospitalized Older Adults
Muscular Atrophy
Primary: The Percent Change in Bilateral Thigh Lean Mass Density (Grams) as Measured by DEXA Scan Will be Compared Between Baseline and After 5-days of Bed Rest — -3.845; -0.249…
Phase 2 N=120 Metformin and Muscle in Insulin-resistant Older Veterans
Prediabetes
Primary: Change in Total Lean Mass From Baseline — 322.8; 697.6; 392.4; 548.0 grams lean mass — p=0.45
N/A N=90 Exercise Training and Glucose Metabolism in Aging
Type 2 Diabetes Mellitus · Impaired Glucose Tolerance (Prediabetes)
Primary: Baseline Glucose Utilization — 0.0062; 0.0035 µmol/kgFFM/pmol insulin/min
N/A N=37 Exercise to Prevent Muscle Mass and Functional Loss in Elderly Dialysis Patients
Chronic Kidney Disease
Primary: Maximal Oxygen Uptake — 14.5; 15.1 ml/kg/min
N/A N=14 Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
Peripheral Arterial Disease · Peripheral Artery Disease
Primary: Endothelial Function — 6.13; 3.78 % dilation
N/A N=30 Nutritional Biomarkers of Sarcopenia
Sarcopenia
Primary: Resting and Maximum Plasma Leucine Concentration — 659; 755; 721; 95 micromoles per liter
N/A N=12 Role of Skeletal Muscle Nitric Oxide Production in Age-related Fatigue and Fatigability
Fatigue · Aging
Primary: Change in Muscle Fatigue After 1 Week of Placebo or Sildenafil — 107; 115; 54; 158 percent change of successful repetitions — p=0.02
N/A N=95 Identifying Therapeutic Targets of Accelerated Sarcopenia
Sarcopenia · Diabetes Mellitus · Aging
Primary: Leg Lean Mass — 0.35; -0.55; -0.80; -0.44 kg — p=<0.01
N/A N=35 Hyperglycemia and Mitochondrial Function in The Endothelium of Humans
Diabetes · Hyperglycemia
Primary: Change in Mitochondrial Network Complexity of Endothelial Cells as Measured by Mitochondrial Network Fragment Ratio
Phase 2 N=26 Trial of Nicotinamide Riboside and Co-enzyme Q10 in Chronic Kidney Disease
Chronic Kidney Disease · Sarcopenia · Frailty
Primary: Maximal Aerobic Capacity- CoQ10 — 21.4; 20.7; 20.7 mL/min/kg — p=0.33
N/A N=44 Immune Function and Muscle Adaptations to Resistance Exercise in Older Adults
Sarcopenia · Aging · Immune Function
Primary: Change in Plasma Concentration of Antibodies to Pertussis Antigen (1 Week Post-vaccine) — 63.1; 63.2 units per ml — p=>0.05
N/A N=9 Translational Control of Anabolic Resistance in Aging Muscle
Physical Inactivity
Primary: Lean Mass — 403 grams
N/A N=32 Brown Adipose Tissue as a Therapeutic for the Metabolic and Cardiac Dysfunction With Senescence (BATSR)
Metabolic Diseases
Primary: Collection of Imaging of BAT by Magnetic Resonance Imaging — 78.69; 82.58; 82.45 Percentage
N/A N=22 Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS
Myopathy · HMG COA Reductase Inhibitor Adverse Reaction · Hypercholesterolemia
Primary: Phosphocreatine Recovery — -18.9; 7.7 percentage change from baseline
N/A N=33 Training Effects on Skeletal Muscle Fatty Acid Metabolism
Healthy Volunteers
Primary: Insulin Sensitivity as Measured by Hyperinsulinemic Euglycemic Clamp at a Single Time Point (6 Hrs) After Intralipid or Glycerol Infusion — 8; 12; 6; 11 M value — p=<0.05
Phase 2 N=6 Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly
Aging
Primary: Leg Blood Flow as Measured by Doppler Ultrasound — 174.99; 102.08; 428.45 ml/minute
N/A N=20 Hepatic Mitochondrial Function in Youth
Hepatic Steatosis · Bariatric Surgery Candidate · Adolescent Obesity
Primary: Change in Percentage of Liver Fat Per MRI — -13.93 percentage of liver fat
N/A N=141 Impact of Protein and Alkali Supplementation on Skeletal Muscle in Older Adults
Age-Related Sarcopenia · Muscle Loss
Primary: Double Leg Press Peak Power at 70% — 260.3; 255.6; 251.1; 264.8 Watts
N/A N=27 Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome
Metabolic Syndrome
Primary: Sarcoplasmic Reticulum Composition — 2.0; 2.2 PC:PE ratio
Phase 2 N=11 Trial of Oral Glutamine on Mitochondrial Function in CKD
Cardiovascular Disease · Sarcopenia · Endothelial Dysfunction
Primary: Muscle Mitochondrial Function — 0.88; 0.90 mM ATP/s — p=0.15
Phase 2 N=11 Mitochondria and Chronic Kidney Disease
Hemodialysis-Induced Symptom · Mitochondrial Diseases
Primary: Phosphocreatine (PCR) Recovery Time After Knee Extension Assessed by 31 Phosphorus Magnetic Resonance Spectroscopy (31P-MRS) — 60.59; 62.66 seconds
N/A N=32 Impaired Regulation of Energy Balance in Elderly People (Balance Study)
Anorexia of Ageing
Primary: Energy Intake Compensation — 1; 1 MJ/day